Atrial Fibrillation and Cardio Oncology

ID: 4121762 Transforming Cardio-Oncology Care with Wearable Technology – Using Smartwatches to Monitor for Arrhythmias in Vulnerable Patient Populations

HeartRhythm

AUGUST 31, 2024

Patients with CLL are at increased risk of developing atrial fibrillation (AF), however AF is a known side effect of ibrutinib therapy as well and is associated with worse outcomes. The incidence of atrial fibrillation (AF) is 10-15% with a median time to occurrence of 5-13 months.

Cardio Oncology

Cardio Oncology Technology Atrial Fibrillation Arrhythmia

Atrioventricular re-entrant tachycardia and atrioventricular node re-entrant tachycardia in a patient with cancer under chemotherapy: a case report and literature review

Frontiers in Cardiovascular Medicine

JUNE 6, 2024

Cardio-oncology is a new field of interest in cardiology focusing on the detection and treatment of cardiovascular diseases, such as arrhythmias, myocarditis, and heart failure, as side-effects of chemotherapy and radiotherapy. The association between chemotherapeutic agents and arrhythmias has previously been established.

Tachycardia

Tachycardia Cancer Cardio Oncology Arrhythmia

Cardiovascular Update

ID: 4121762 Transforming Cardio-Oncology Care with Wearable Technology – Using Smartwatches to Monitor for Arrhythmias in Vulnerable Patient Populations

Atrioventricular re-entrant tachycardia and atrioventricular node re-entrant tachycardia in a patient with cancer under chemotherapy: a case report and literature review

Stay Connected